Namilumab Reduces Inflammation, May Improve Outcomes in COVID-19 Pneumonia
A small study evaluated whether the use of 2 anti-inflammatories, namilumab and infliximab, could improve outcomes for patients with COVID-19 pneumonia.
Related Articles
Food Allergy/Asthma Risk Linked to Early Childhood Metabolomic Profiles
Researchers identified metabolites which are unique to and shared by children with food allergy and/or asthma, using birth cohort data from inner city children.
High Suspicion Crucial to Identifying Pediatric Egg-Induced Anaphylaxis
Investigators described the clinical characteristics, management, and outcomes of pediatric egg-induced anaphylaxis.
AIRQ Tool Heightens Awareness of Uncontrolled Asthma, Exacerbation Risk
Researchers evaluated how AIRQ compared with other asthma evaluation modalities in assessing asthma control and predicting exacerbation risk.
Online Resources for Inhaler Therapy Omit Important Information
Researchers evaluated the reliability and accuracy of online resources describing inhaler techniques, comparing online information with product profiles.
Diagnosis & Disease Info – Pulmonology Advisor
Pneumonitis refers to inflammation of the lungs that is triggered by allergens, environmental irritants, and certain medications.
Prolonged Virus Detection Common in Healthy Children With Respiratory Infections
Researchers examined factors associated with prolonged viral shedding and detection among a cohort of healthy children with respiratory infections.
Cough Severity May Predict Disease Progression in Fibrotic ILD
Researchers analyzed the relationship between cough severity in fibrotic ILD and patients’ baseline clinical parameters, disease progression, and prognosis.
Who is Most Likely to Quit Asthma Multi-Inhaler Triple Therapy After 6 Months?
Researchers characterized the clinical features, treatment regimens, and demographics of patients with asthma who initiated MITT and subsequently quit vs continued.
Fasenra Approved for Pediatric Patients With Severe Eosinophilic Asthma
Previously, the treatment had only been approved for patients 12 years and older.
Adjuvant Alectinib Improves Disease-Free Survival in Lung Cancer
Findings seen among patients with resected ALK-positive non-small cell lung cancer